Featured Stories

  • The COVID Heart - One Year After SARS-CoV-2 Infection, Patients Have an Array of Increased Cardiovascular Risks

    The COVID Heart - One Year After SARS-CoV-2 Infection, Patients Have an Array of Increased Cardiovascular Risks Published March 2, 2022: JAMA doi: 10.1001/jama.2022.2411

    Learn More

  • Long-term Cardiovascular Outcomes of COVID-19

    Long-term cardiovascular outcomes of COVID-19 Published Feb. 7, 2022: Nature Medecine  https://doi.org/10.1038/s41591-022-01689-3  

    Learn More

  • Understanding Pulmonary Arterial Hypertension Outcome Measures

    Pulmonary arterial hypertension (PAH) is a rare, life-threatening condition characterized by elevated blood pressure in the arteries which carry blood from the heart to the lungs. The high blood...

    Learn More

  • Calgary-based biotech firm specializes in instructing cells to fight complex diseases

    Imagine a world where a host of diseases and conditions caused by non-beneficial instructions from our DNA could be treated simply by instructing our cells to ignore those signals. That science is...

    Learn More

  • Health Matters: Alberta-developed drug could help prevent long COVID

    Health Matters February 2: Calgary company Resverlogix has developed a drug that could not only stop COVID-19 illness from progressing, it also has potential to prevent chronic symptoms, or long...

    Learn More

  • Calgary Company's COVID Drug Going to Phase Two Trials

    Calgary-based biotech company Resverlogix moves into a phase two clinical trial for an oral treatment Apabetalone for COVID-19. And they are looking for patients to participate in the study....

    Learn More

  • Made-in-Alberta drug being tested on COVID-19 patients

    New drug trial to treat COVID-19 patients has been launched at the University of Alberta. Hiba Kamal-Choufi reports.

    Learn More

  • 'Exciting breakthrough': COVID-19 drug trial to take place in Edmonton

    Trials for a Canadian-developed COVID-19 treatment are set to begin at the University of Alberta. CTV News Edmonton - Aired January 24, 2022

    Learn More

  • An Alberta-developed oral treatment for COVID-19 has begun testing at the University of Alberta hospital

    J'lyn Nye interviews RVX President & CEO Donald McCaffrey about our Phase 2b COVID-19 Clinical Trial on 630 CHED

    Learn More

  • Some COVID-19 patients in Edmonton begin potential trial treatment, apabetalone, an Alberta-developed drug

    By Kellen Taniguchi Edmonton Journal, January 18, 2022  

    Learn More

  • Epigenetic Therapies Start Operating Outside the Lines

    Drug developers are sourcing novel structures, bridging transcriptional and signaling domains, and exploring applications beyond oncology GEN: Genetic Engineering and Biotechnology News...

    Learn More

  • Resverlogix in Active Discussions with Morocco

    Resverlogix is in active discussions for COVID-19 clinical studies in Morocco involving apabetalone.

    Learn More

  • Donald McCaffrey at Benzinga All Access

    Resverlogix President & CEO Donald McCaffrey presents at Benzinga All Access conference 2021

    Learn More

  • Resverlogix: The Future of Drug Development

    Clip of Donald McCaffrey, President & CEO of Resverlogix which aired on Fox News December 18, 2021.   © 2021 www.B-TV.com . All Rights Reserved.  

    Learn More

  • Apabetalone meets primary endpoint in PAH pilot study

    Resverlogix reported that its lead drug apabetalone met its primary endpoint in a pulmonary arterial hypertension or ‘PAH’ investigator led pilot study. Watch the news...

    Learn More

  • EVERSANA & Resverlogix Discuss Partnership On PharmaVOICE Webinar

    Rohit Sood, EVP, COMPLETE Commercialization, EVERSANA / Donald McCaffrey, President & CEO, Resverlogix: Next Generation Commercial Innovation: Moving From Promise to Practice. 

    Learn More

  • Donald McCaffrey featured on Innovators with Jane King

    Donald McCaffrey, President & CEO of Resverlogix featured on Innovators with Jane King. Latest updates on the Company's COVID-19 program.

    Learn More

  • COVID-19 Program Update with Donald McCaffrey

    CEO Donald McCaffrey joined PBA à Noon, for a live webinar and Q&A, to discuss the latest developments in Resverlogix' COVID-19 program.

    Learn More

  • Health Canada Authorizes COVID-19 Clinical Study

    Resverlogix receives "No Objection Letter" from Health Canada, approving the COVID-19 Clinical Trial Application for apabetalone.

    Learn More

  • Apabetalone May Prevent Heart Damage Caused by COVID-19

    COVID-19 affects not only lung and respiratory tissue but can injure your heart as well. One study, published in the Journal of the American Medical Association, found that 78% of recently...

    Learn More

  • Balancing Epigenetics in the Treatment of Chronic Kidney Disease

    Kidneys are the body’s filtration system . They clean our blood, removing waste and helping manage blood pressure by controlling the outflow of water. Unfortunately, when these filters...

    Learn More

  • Targeting Epigenetics as a New Therapy in Vascular Disease and Dementia

    Cardiovascular disease literally means disease of the heart and blood vessels, but it can cause additional life-altering complications that we might not initially associate with the disease,...

    Learn More

  • The Faces of Cardiovascular Disease: Series Final

    This is the final article of the mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men...

    Learn More

  • The Faces of Cardiovascular Disease: Part 4

    This article is part of a mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men and women...

    Learn More

  • The Faces of Cardiovascular Disease: Part 3

    This article is part of a mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men and women...

    Learn More

  • The Faces of Cardiovascular Disease: Part 2

    This article is part of a mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men and women...

    Learn More

  • The Faces of Cardiovascular Disease: Part 1

    This article is part of a mini-series we are calling The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of...

    Learn More

  • Apabetalone: A Relative Size Animation

    Our lead compound – apabetalone – is the first small molecule of its kind with potentially important benefits for patients with high-risk cardiovascular and other chronic diseases. But...

    Learn More

  • The Faces of Cardiovascular Disease: Part 1

    This article is part of a mini-series we are calling The Faces of Cardiovascular Disease, looking at the different presentations, symptoms, and root causes of a disease that affects millions of men and women around the world.

    Through this series we hope to explore the human side of the problem, to develop a deeper and more companionate understanding of the stories behind the figures, and ultimately to better inform the products we develop.

     

    We have all heard the statistic; you’re more likely to die from cardiovascular disease than from any other cause.

    In fact, between 1980 and 2014, 4 in 10 deaths in the United States – 31.9 million people – were a direct result of cardiovascular disease. A sobering figure, but what’s equally alarming is the acceptance of this sad reality rather than asking fundamental questions that may lead to real solutions.

    To start, what’s behind these numbers? Am I at risk of suffering a heart attack? A stroke?  What could cause my disease? Is it genetic? Did lifestyle choices contribute? Can I prevent this from happening?

    Statistics only tell part of the story.

    By digging deeper into the personal stories of those affected we can uncover the root causes of cardiovascular disease and look towards more effective preventions and therapies.

    As a research-based biotechnology company, Resverlogix first and foremost tries to understand the biology underlying cardiovascular disease. However, through this series we hope to explore the human side of the problem, to develop a deeper and more companionate understanding of the stories behind the figures, and ultimately to better inform the products we develop.

    Let’s get into it, starting with some terminology. When we’re referring to cardiovascular disease what exactly are we talking about?

    Cardiovascular disease isn’t a single disease at all.

    It’s a general term used to describe a diverse array of disorders and dysfunctions that affect the heart or blood vessels. However, the shared anatomy is not the only commonality of these diseases; despite variability in presentations, cardiovascular diseases often share a few broad underlying processes.

    Atherosclerosis – the formation of lipid-filled plaque in the walls of blood vessels – is one of the most common and important processes contributing to cardiovascular disease. In its most severe form, atherosclerosis can result in complete blockages of blood vessels. When this occurs in the coronary arteries – the vessels that feed the heart muscle – it causes a heart attack; if the blockage occurs in the arteries providing oxygen to the brain, a stroke can result. Together, heart attacks and strokes account for nearly 80% of cardiovascular disease-related deaths.

    Another common process, Hypertension, or high blood pressure in the arteries, causes the heart muscle to work harder than normal. As wear accumulates, these tissues may not be able to keep up with the extra stress leading to heart failure, aneurysms, and strokes. Hypertension is often called the “silent killer” as symptoms may not be apparent until it has already caused significant damage.

    The deposition of calcium-rich minerals, a process normally reserved for bone growth and remodeling, occurring inside arterial walls is characteristic of cardiovascular disease. This calcification can occur in the valves of the heart reducing flow, while calcification of major arteries causes them to stiffen, both of which cause the heart to work harder to maintain sufficient blood flow.

    Chronic inflammation – the persistent activation of the immune system – is strongly associated with the multitude of factors and dysfunctions that contribute to cardiovascular disease. Molecular mechanisms designed to protect the body against foreign invaders become a real danger instead, as small tissue damage accumulates over years or decades.

    These processes are not isolated from one another.

    Inside arteries, chronic inflammation kicks off the development of atherosclerosis; reduced filtration capacity in the kidneys, caused by calcification, raises blood pressure.

    When we go one step deeper, into the basic functioning of the body at a cellular and molecular level we find that each of these processes is dependent on genetic and epigenetic factors.

    Some examples of genetic contributions to cardiovascular disease are obvious – such as congenital defects of the heart, present at birth. However, genetic factors can also have a more subtle, cumulative impact, causing a slow but critical decline in cardiovascular health. They may also predispose a patient to the development of hypertension, high cholesterol, obesity, diabetes, or chronic inflammation.

    But genetics alone don’t tell the whole story, with epigenetics – the process by which genes get turned “on” or “off” – playing a crucial role. Epigenetics is the mechanism by which environmental and lifestyle factors are translated into health outcomes.

    Our research group has published a number of papers showcasing the epigenetic basis underpinning lipid metabolism, calcification, and inflammation.

    In our series, we will examine the lives of different people with cardiovascular disease and try to understand how genetic and environmental risk factors, translated through epigenetics and the intertwined processes of lipid transport, hypertension, inflammation and calcification, ultimately combine to impact their lives.

    Thankfully, much of the harm associated with cardiovascular disease is preventable.

    Multiple studies have shown changes in lifestyle can prevent serious cardiovascular events in predisposed populations. In the last 30 years, new advances in treatment and management have cut the deaths associated with cardiovascular disease in half.  

    This is reason to be optimistic. In the final installment of this series we will look at some of the things science tells us you can do to reduce your risk of cardiovascular disease, as well as taking a peek at what’s on the horizon in terms of new treatment options.